Combination of Apigenin and Melatonin with nanostructured lipid carriers as anti-inflammatory ocular treatment.
Study Goal
The researchers aimed to determine whether Apigenin (APG), combined with Melatonin (MEL) and nanostructured lipid carriers (NLC), could effectively treat ocular inflammation by reducing cytokine levels and inflammation in vitro and in vivo.
Results Summary
The study found that APG and MEL co-encapsulated in NLC reduced inflammatory cytokines (IL-6, IL-8, MCP-1) and inflammation in a rabbit model, with sustained release and biocompatibility. Limitations include the need for further human trials to confirm efficacy and safety.
Population
In vitro testing used a corneal cell line, and in vivo testing was conducted on a rabbit model of ocular inflammation.
Effective Dosage
Not specified in the abstract.
Duration
Not specified in the abstract, but effects were observed in both acute (in vitro) and sustained (in vivo) contexts.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Apigenin (APG) and Melatonin (MEL) in combination with nanostructured lipid carriers (NLC) | decrease | treating ocular inflammation | - | - | may provide a synergistic effect | #1 |
Apigenin (APG) and Melatonin (MEL) in combination with nanostructured lipid carriers (NLC) | increase | patient outcomes | - | - | potentially improving | #2 |
Apigenin (APG) and Melatonin (MEL) in combination with nanostructured lipid carriers (NLC) | decrease | adverse effects | - | - | reducing | #3 |
nanostructured lipid carriers (NLC) | neutral | these compounds | - | - | could provide chemical protection | #4 |
nanostructured lipid carriers (NLC) | neutral | into the ocular surface | - | - | offering a sustained release | #5 |
Optimized NLC | neutral | suitable physicochemical parameters | - | - | exhibited | #6 |
Optimized NLC | neutral | physical stability | - | - | exhibited | #7 |
Optimized NLC | neutral | sustained release of APG and MEL | - | - | exhibited | #8 |
Optimized NLC | neutral | - | in vitro with a corneal cell line | - | were biocompatible | #9 |
Optimized NLC | neutral | - | in ovo by using hen's egg chorioallantoic membrane test | - | were biocompatible | #10 |
NLC | decrease | interleukin-6 (IL-6), IL-8 and monocyte chemoattractant protein 1 (MCP-1) cytokine levels | in vitro and in vivo studies | - | ability to attenuate inflammation by reducing | #11 |
NLC | decrease | inflammation | in a rabbit model | - | ability to attenuate inflammation by decreasing | #12 |
co-encapsulation of APG and MEL into NLC | decrease | ocular inflammatory conditions | - | - | could represent a promising strategy for managing | #13 |
Ocular inflammation is a complex pathology with limited treatment options. While traditional therapies have side effects, novel approaches, such as natural compounds like Apigenin (APG) and Melatonin (MEL) offer promising solutions. APG and MEL, in combination with nanostructured lipid carriers (NLC), may provide a synergistic effect in treating ocular inflammation, potentially improving patient outcomes and reducing adverse effects. NLC could provide chemical protection of these compounds, while offering a sustained release into the ocular surface. Optimized NLC exhibited suitable physicochemical parameters, physical stability, sustained release of APG and MEL, and were biocompatible in vitro with a corneal cell line, and in ovo by using hen's egg chorioallantoic membrane test. In vitro and in vivo studies confirmed the NLC' ability to attenuate inflammation by reducing interleukin-6 (IL-6), IL-8 and monocyte chemoattractant protein 1 (MCP-1) cytokine levels and by decreasing inflammation in a rabbit model. These findings suggest that the co-encapsulation of APG and MEL into NLC could represent a promising strategy for managing ocular inflammatory conditions.